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Angioedemaof the upper airways is a severe and potentially life-threatening condition.The incidence has been increasing in the past
two decades, primarily due to pharmaceuticals influencing the generation or degradation of the vasoactive molecule bradykinin.
Plasma-derived C1-esterase inhibitor concentrate is a well-established treatment option of hereditary and acquired complement
C1-esterase inhibitor deficiency, which are also mediated by an increased level of bradykinin resulting in recurrent angioedema.
We here present a case of severe angiotensin converting enzyme-inhibitor related angioedema (ACEi-AE) of the hypopharynx that
completely resolved rapidly after the infusion of plasma-derivedC1-inhibitor concentrate adding to the sparse reports in the existing
literature.
1. Introduction
More than 40 million people worldwide are currently treated
with angiotensin converting enzyme- (ACE-) inhibitors due
to cardiovascular or renal disease [1]. The primary mech-
anism of angiotensin converting enzyme-inhibitor related
angioedema (ACEi-AE) is accumulation of bradykinin
(Figure 1). The incidence is reported to be 0.1–2.2% of
exposed individuals [1, 2]. Thus, more than 400,000 cases
of angioedema are to be expected worldwide yearly. ACEi-
AE is a severe and potentially lethal condition due to its pre-
dilection for the subdermis and submucosa of the head and
neck area, causing a serious risk of asphyxiation in these
patients [3, 4]. Knowledge of the diagnosis and correct treat-
ment options are crucial and potentially life-saving.
2. Case Presentation
A 56-year-old Caucasian male presented with a sensation of
swelling in the throat, hoarseness, difficulty swallowing, and
slight soreness in the right side of the throat. The symptoms
were present when the patient awoke in the morning and
progressed in a few hours, which caused him to seek medical
assistance. At the local emergency department, a swollen
tongue was found and the on-call otorhinolaryngologist was
contacted. The patient had no known food allergies and
no previous history of angioedema or urticarial eruptions.
The patient did not present any signs of anaphylaxis (e.g.,
urticarial eruption, pruritus, hypotension, bronchospasm, or
vomiting). It was unravelled that the patient 5 years ago
was taking an ACE-inhibitor as an antihypertensive drug
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ACE-inhibitors effect on bradykinin levels
Bradykinin is degraded by the
angiotensin converting
enzyme (ACE)
Other enzymes to degrade
bradykinin are not sufficient?
(i) Carboxypeptidase N
(ii) Aminopeptidase P
(iii) Neutral endopeptidase
(iv) Dipeptidyl peptidase IV 
Increased risk of angioedema in
predisposed individuals
Pharmaceuticals
inhibiting ACE → raised
levels of bradykinin
Figure 1: Some scientists hypothesize that patients might be
predisposed to develop angioedema due to DNA mutations in the
genes encoding the enzymes of the bradykinin pathway [5–10].
on a daily basis and thus bradykinin mediated angioedema
was suspected. The patient was immediately transferred to
the department of otorhinolaryngology. On admission, the
symptoms were unchanged and the vital signs were normal.
Lung and heart auscultationwere normal.The clinical otorhi-
nolaryngological assessment showed amoderate angioedema
of the right side of the base of the tongue, the uvula, and the
right palate-pharyngeal arch. Fibre-optic assessment of the
pharynx showed a moderate swelling of the right side of the
lingual tonsil and a severe mucosal swelling of the right side
of the hypopharynx, the piriform sinus, the right aryepiglottic
fold, and the right ventricular fold. The vocal folds were
unaffected. Articulationwas slightly impaired by the swelling.
The voice was hoarse, but the respiration was unaffected.
Besides a single small and sore lymph node on the right side
of the neck, there were no palpable cervical lymph nodes. A
bedside sonography of the neck revealed an inconspicuous
lymph node with normal hilar flow in level Ib/II equivalent to
the palpable lymphnode. Blood samples (electrolytes, red and
white blood cell count, and C-reactive protein) were normal
except for a subnormal level of P-potassium 3.0mmol/L (3.5–
4.5mmol/L). Since there were no signs of an anaphylactic
reaction, tryptase was not measured. The patient did not
present with symptoms and clinical findings compatible to
upper airway infection (no fever, odynophagia, mucosal
hyperaemia, or lymphadenitis). The patient had earlier suf-
fered from a single deep vein thrombosis and was known
to have type 2 diabetes, hypertension, hypercholesterolemia,
and secondary polycythaemia due to smoking. He had no
positive family history for angioedema and no prior swelling
episodes. The medical history did not reveal any signs of
allergic disease or malignancy. Complement analysis was not
performed in the acute phase, as the biochemical analysis
requires several days.
On admission, 40 milligrams of corticosteroid (Solu-
Medrol) had initially been administered intravenously.
However, as the history revealed, ACEi-AE was suspected
and an effect of corticosteroid could not be expected and was
not awaited. Treatment with antihistamine was expected to
be ineffective; thus, an antihistamine was not administrated.
On suspicion of ACEi-AE, 2000 units of (18 units/kg) plasma-
derivedC1-inhibitor concentrate (Berinert) was administered
intravenously over a course of 10 minutes.The patient rapidly
reported to have decreased symptoms, but a fibre-optic
reassessment was not performed until 5 hours after the
infusion. A significant decrease in severity of the angioedema
was observed. The patient was observed in the in-patient
department for 24 hours and at discharge the angioedema
had completely resolved, which was confirmed by fibre-optic
reassessment. At the time of admission, the patient received
an ACE-inhibitor, a calcium-antagonist, acetylsalicylic acid,
a statin, and a non-beta-cell stimulating antidiabetic drug
(Metformin). The patient was thoroughly instructed never
to take ACE-inhibitor again. The patient was enrolled in
a large international multicenter DNA sequencing study
(Prediction-ADR) in which further evaluation, including
DNA testing for geneticmutations in the bradykinin pathway,
is currently performed.
3. Discussion
As well as facial and/or oropharyngeal swelling, abdomi-
nal/intestinal pain may also occur in ACEi-AE.
Facial and/or oropharyngeal swelling may occur as part
of an anaphylactic/allergic reaction which must be ruled out,
since the condition can rapidly progress when not treated
correctly with antiallergicmedicine. Inmost cases, symptoms
from other organs are present (e.g., urticarial eruption,
hypotension, bronchospasm, and/or vomiting).
Hereditary angioedema (HAE) can be caused by excessive
bradykinin formation due to complement C1-inhibitor defi-
ciency but is also seen in patients with normal C1-inhibitor
function [11]. A minor fraction of patients with normal C1-
inhibitor function have mutations of factor XII and some
might have estrogen dependent hereditary angioedema [11].
Seventy-five percent will have a family history of angioedema
and most adults present with a history of prior angioedema
attacks and/or recurrent abdominal pain episodes since
childhood or early adulthood [12]. In 20–25% of patients with
HAE there is no family history, as they represent de novo
mutations [13].The diagnosis is made on the basis of comple-
ment C1-inhibitor antigenic level and function, complement
C4, and complement C1q concentration. Another differential
diagnosis is acquired angioedema (AAE) most often associ-
ated with malignant diseases where increased catabolism as
well as production of anti-C1-inhibitor antibodies leads to
diminished levels of complement C1-inhibitor [14]. Systemic
symptoms such asweight loss, fatigue, night sweats, fever, and
low C1q level in association with angioedema should raise
suspicion on AAE.
Other differential diagnoses to be considered are idio-
pathic angioedema (which rarely become life-threatening),
granulomatous disease, or localised disease in the larynx,
which do not have an acute onset.
The patient received acetylsalicylic acid which has angi-
oedema listed as extremely rare adverse effect, but the ACE-
inhibitor was by far the most suspicious pharmaceutical on
the list.
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There is no consensus regarding the treatment of ACEi-
AE, but as bradykinin is the suspected offending molecule it
has been proposed to use a bradykinin receptor antagonist
(icatibant) which, in this case, was not available [15].Thus, the
patient was treated with plasma-derived C1-esterase inhibitor
(Berinert) since there have been previous reports regarding
the efficacy of this drug in severe ACE-inhibitor related
angioedema [16–19]. Plasma-derived C1-esterase inhibitor
concentrate is registered for treating HAE, but reports on
successful outcome in patients with ACEi-AE support the
use in this group of patients. Treatment with plasma-derived
C1-esterase inhibitor concentrate is thought to decrease the
production of bradykinin thus allowing the preexisting excess
bradykinin to be degraded to inactive bradykininmetabolites
[20].
Accumulation of bradykinin is responsible for angi-
oedema episodes in HAE and AAE as well as in ACEi-AE.
Drugs interferingwith the pathway leading to increased levels
of bradykinin are well documented in the treatment of HAE
and AAE [21, 22]. However, in ACEi-AE of the head and neck
only one study has described the effect of a bradykinin B2
receptor antagonist (icatibant) compared to traditional treat-
ment with glucocorticoids and antihistamines. The median
time for complete resolution in the icatibant group was 8.0
hours (3.0–16.0 hours) compared to 27.1 hours (20.3–28.0
hours) in patients treated with glucocorticoids and antihis-
tamines [15]. Successful treatment with plasma-derived C1-
inhibitor concentrate (Berinert) in patients with ACEi-AE
has been described in a few case reports [16–19]. It was even
found that the use of plasma-derived C1-inhibitor concen-
trate decreased mechanical ventilation time [23]. A study
comparing the effect of a plasma-derived C1-inhibitor con-
centrate to glucocorticoids and antihistamines is currently
being carried out (clinical trial number: NCT01843530) [24].
Other reports describe successful outcomes when treating
ACEi-AE with fresh frozen plasma, but in Denmark this is
not the first-choice treatment [25].
The genetic aspects of ACEi-AE are a new topic to be
investigated and interesting studies have been carried out in
recent years. The main challenge is to include a substantial
number of patients, as the diagnosis is not always straight-
forward. A few mutations have, however, been identified [5–
10, 26]. More studies are currently ongoing, and the patient
in this case report was enrolled in a large international
multicenter DNA sequencing study (Prediction-ADR), in
which the genes involved in the bradykinin pathway will be
assessed for disease causing polymorphisms. The patient will
also be subjected to clinical follow-up (telephone interview)
regarding recurrent angioedema episodes, as it is known that
11% of patients with ACEi-AE will experience relapses even
when the offending medication has been discontinued [27].
Patients with ACEi-AE in the head and neck are often
admitted to the emergency department where initial treat-
ment is carried out. Knowledge of the mechanisms and
treatment options in ACEi-AE is crucial since progression
of the angioedema may lead to compromised airway and
death [28]. Furthermore, it is very important to discontinue
the medication and inform the patient of the connection, as
continuation poses a severe risk of new angioedema attacks
[29]. This should be followed by adequate testing necessary
to exclude C1-inhibitor deficiency. As there is no test for
identifyingACEi-AE, excluding C1-INHdeficiency should be
an essential component of the diagnostic evaluation.
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